Home › Compound Library › Epitalon
Longevity and bioregulation
Epitalon: Four Amino Acids, Telomerase, and What the Research Actually Shows
The short answer
Epitalon is a four-amino-acid peptide modelled on epithalamin, an extract of the pineal gland. It is the compound most associated with telomerase research in the longevity world, on the strength of laboratory work and a long Russian research programme. In July 2026 an FDA advisory committee recommended it for pharmacy compounding.
Questions people ask about Epitalon
Epitalon at a glance
| Also called | Epithalon; AEDG peptide (Ala-Glu-Asp-Gly) |
|---|---|
| What it is | A synthetic tetrapeptide modelled on the pineal extract epithalamin |
| Acts on | Telomerase expression; pineal and melatonin rhythm; gene expression |
| Main system | Longevity: cellular ageing, circadian rhythm, endocrine regulation |
| Evidence level | Laboratory and animal work plus long-running Russian clinical studies; little independent replication |
| FDA status (Sept 2026) | Not approved. Recommended by an FDA advisory committee in July 2026 for the list of substances pharmacies may compound |
| In sport | Not named on the 2026 WADA prohibited list |
What is epitalon?
The pineal gland sits deep in the brain and governs melatonin and the body’s sense of day and night. Russian researchers working on pineal extracts in the 1980s isolated a preparation called epithalamin, and later identified a four-amino-acid sequence that carried much of the activity. That sequence, Ala-Glu-Asp-Gly, is epitalon.
Four amino acids is about as small as a peptide gets. That is part of the interest: small enough to reach places larger peptides cannot, and cheap enough to make that it has been studied for decades without commercial backing.
Targeted Peptide Systems profiles it at pp. 104–107, The Cognitive Advantage at pp. 174–182, and The Longevity Map at pp. 92–94 and pp. 108–109.
How does epitalon work?
Telomerase is the headline. Telomeres are the protective caps on chromosomes, and they shorten each time a cell divides. Telomerase is the enzyme that rebuilds them, and it is largely switched off in adult somatic cells. A 2003 study in Bulletin of Experimental Biology and Medicine reported that epitalon induced telomerase activity and telomere elongation in human somatic cells in culture (reference 1), and a follow-up reported cells dividing beyond their usual limit (reference 2).
The bioregulator idea. The Russian research tradition treats short peptides as gene-expression signals: molecules small enough to reach DNA-associated proteins and influence which genes are read in a given tissue. Epitalon is the most-studied example of that idea.
Melatonin and rhythm. Because of its pineal origin, much of the animal work concerns restoring melatonin rhythms that flatten with age, which is a plausible route to several of the downstream effects reported.
The Longevity Map (pp. 53–55) places it among the bioregulators and is careful about the evidence tier it assigns them.
What does the research show?
The cell work. The telomerase and telomere-elongation findings are the reason anyone is interested (references 1, 2). They are laboratory results in cultured human cells, not results in people.
The animal work. Studies in rats reported effects on lifespan and on the development of spontaneous tumours, run over decades by the same research group.
The human work. The most substantial human data is a 15-year follow-up of elderly patients given the pineal preparation, published in 2011, reporting reduced mortality in the treated group (reference 3). That is a long and unusual dataset. It is also from the same research group that developed the compound, with the limitations that implies.
Where the evidence stands. What epitalon has is a long and internally consistent record: cell work, decades of animal studies, and a fifteen-year human follow-up, nearly all of it from one research programme. Consistency across that span is a reason to take the compound seriously, and a reason to want a second group to run the same experiment.
Side effects and cautions
Across decades of animal work and the Russian clinical studies, the toxicology has stayed quiet. No characteristic side-effect profile has emerged, and the quantities involved are very small.
That is a good starting position. It is not the same thing as the systematic long-term monitoring a Western approval process produces, which is the piece still to come.
The theoretical caution worth naming honestly is the telomerase mechanism itself. Telomerase activation is also a feature of many cancers, and a compound that switches it on invites the question of what that does in a body that already has abnormal cells. Nothing in the research to date shows harm, and the animal tumour data points the other way. But this is the one mechanism in this library where the open question deserves a specific conversation with a clinician who knows your history.
The practical risk is the same as for anything sold outside a regulated supply chain: purity and identity depend on the supplier.
Is epitalon legal or FDA approved?
Not FDA approved. On 23–24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee recommended epitalon for the 503A bulks list, one of six peptides it recommended that day (references 4, 5). The vote is a recommendation. It is not binding, and formal rulemaking has to follow before compounding pharmacies can use it.
Sport: epitalon is not named on the 2026 WADA prohibited list. Check with your sport’s governing body, as lists are updated annually.
This page is reviewed and updated as the status changes.
Epitalon vs the other bioregulators and longevity compounds
The compounds epitalon is compared with are aiming at different parts of ageing.
- vs the other bioregulators (thymalin, cartalax, sigumir and the rest): the same research tradition and the same short-peptide logic, each aimed at a different tissue. Regenerative Resilience and The Longevity Map treat them as a family rather than as individual compounds.
- vs MOTS-c: MOTS-c works on mitochondrial signalling and metabolic stress. Epitalon works on gene expression and cellular ageing. Different levels of the same problem.
- vs thymosin alpha-1: both address systems that decline with age, one immune and one cellular, and thymosin alpha-1 has by far the stronger clinical evidence base.
- vs NAD+ strategies: aimed at cellular energy rather than at telomeres. The Longevity Map (pp. 53–55) sets out how it tiers these by evidence rather than by popularity.
Our article on the cellular battery problem covers why the energy layer usually has to be addressed before anything else shows a result.
Risk, benefit, and the conversation this page is for
What epitalon has is a long and internally consistent record. Cell work, decades of animal studies and a fifteen-year human follow-up all point the same way — and a fifteen-year follow-up is something almost nothing else in this field has ever attempted. Most of it comes from one research programme, which is a reason to take the compound seriously and a reason to want a second group to run the same experiment. The toxicology has stayed quiet throughout. One caution deserves its own conversation, the telomerase mechanism, and the safety section above is where we make that case.
The regulatory picture is moving, and it is moving one compound at a time. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. The same committee has turned peptides down and still does: ipamorelin and CJC-1295 sit in Category 2, barred from compounding. The distinction is the useful part. Each compound is being read on its own risk record rather than lumped under one verdict called unapproved.
The clinicians working with these compounds are not fringe, and their reasoning is comparative rather than enthusiastic. The approved options for chronic inflammation and slow-healing tissue carry burdens that are thoroughly documented: long-term anti-inflammatories on the gut and kidneys, repeated corticosteroid injections on connective tissue, glucose control and bone. Weighed against that, a compound with a quiet toxicology record and an incomplete efficacy record is a reasonable thing to discuss. It is not a reasonable thing to promise, and that is the line this page tries to hold.
Which is the point of the series. Nothing here is a recommendation to use epitalon. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
Epitalon: frequently asked questions
What is epitalon?
A four-amino-acid peptide (Ala-Glu-Asp-Gly) modelled on epithalamin, a pineal gland extract. It is studied as a bioregulator, meaning a short peptide that influences gene expression.
Does epitalon lengthen telomeres?
In cultured human cells, a 2003 study reported induced telomerase activity and telomere elongation (reference 1). That is a laboratory result in cells, and it has not been shown the same way in people.
Is epitalon FDA approved?
No. In July 2026 an FDA advisory committee recommended adding it to the list of substances compounding pharmacies may use, which is a non-binding step and not an approval (references 4, 5).
What is the difference between epitalon and epithalon?
Nothing. They are two spellings of the same peptide, and epithalamin is the original pineal extract it was modelled on.
Does epitalon work in humans?
The most substantial human data is a 15-year follow-up of elderly patients given the pineal preparation, reporting reduced mortality (reference 3). It comes from the group that developed the compound, and no second group has yet run a study of that length.
What are epitalon’s side effects?
No characteristic side-effect profile has emerged across decades of animal and Russian clinical work, and the quantities involved are very small. Systematic long-term monitoring of the kind an approval process produces is still to come.
Can epitalon cause cancer?
Nothing in the research to date shows that, and the animal tumour data points the other way. The question is worth asking because telomerase activation is also a feature of many cancers, which makes this a specific conversation to have with a clinician who knows your history.
Is epitalon banned in sport?
It is not named on the 2026 WADA prohibited list. Check with your sport’s governing body, as lists change each year.
Where Epitalon appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how Epitalon fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Books marked Look Inside include these exact pages in their free preview.
Related compounds
See how Epitalon fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. View sourceCited in Metabolic Precision (p. 357)
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503–506. View source
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366–369. View source
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Epitalon is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.